| SFDA Approved Use |
Liposomal amphotericin is indicated in adults and children aged 1 month to 18 years old for:
• the treatment of severe systemic and/or deep mycoses; • the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children; • the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause. Infections successfully treated with liposomal amphotericin include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis. Liposomal amphotericin should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.